Search
  • rpierce2019

Leveraging Synthetic Biology to Create Better Treatments For Lynch Syndrome and FAP

Updated: May 18

Engineered Nissle bacteria has been previously tested pre-clinically and in Phase 2 clinical trails. It was well tolerated and elucidated desired biologic effects. This is why we are engineering Nissle bacteria for human clinical evaluation in a variety of rare diseases.

#engineeredbacteria #geneswitches #platformtechnology #raredisease #Nissle1917 #sanaRx #Cancer #geneticcancers #Colorectalcancer #FAP #Lynchsyndrome

In Clinical Trails Engineered Nissle Was Shown to Well Tolerated and Clear The Gut

23 views

Contact

Follow

6174478299

©2019 by FEP Capital Advisors, LLC.